Search Within

Pedram Razavi

  1. "Early Drug Development Service"
Formats
  1. Journal Article (14)
  2. Meeting Abstract (10)
  3. Research Letter (1)
Groups
  1. Breast Medicine Service (25)
  2. Department of Medicine (25)
  3. Early Drug Development Service (25)
  4. Solid Tumor Oncology Division (25)
  5. Weinberg Fellows (25)
  6. GSK Faculty (24)

More Groups

People
  1. David Hyman (23)
  2. Michael Berger (14)
  3. Marc Ladanyi (13)
  4. David Solit (12)
  5. Jose Baselga (12)
  6. Sarat Chandarlapaty (12)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (7)
  5. 2019 (5)
  6. 2018 (4)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Cancer Research (4)
  3. Nature Medicine (3)
  4. Cancer Discovery (2)
  5. Journal of Molecular Diagnostics (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (6)
  3. Nature Publishing Group (5)
  4. Elsevier Science, Inc. (2)
  5. American Association for the Advancement of Science (1)
  6. American Medical Association (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Journal Article

    Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
    Nature Medicine (2017)

    Fulltext@MSK | Save
  • Next-generation assessment of human growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay
    Journal Article

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Benayed, R.; Nafa, K.; Hechtman, J. F.; Janjigian, Y. Y.; Weigelt, B.; Razavi, P.; Hyman, D. M.; more...
    Journal of Molecular Diagnostics (2017)

    Fulltext@MSK | Save
  • Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)
    Meeting Abstract

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays
    Meeting Abstract

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Nafa, K.; Jour, G.; Razavi, P.; Hyman, D. M.; Baselga, J.; Berger, M. F.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save